Efficacy and safety of dupilumab in the treatment of prurigo nodularis
Objective:To evaluate dupilumab effectiveness and tolerability in treating patients with prurigo nodularis(PN).Methods:A retrospective study was conducted on patients affected by PN,who were treated with dupilumab for at least 16 weeks.Efficacy was assessed using the Investigator's Global Assessment(IGA),Patient Oriented Eczema Measure(POEM),Numerical Rating Scale(NRS)and Dermatology Life Quality Index(DLQI)at weeks 0,6,10 and 16.Adverse reaction during the treatment period were also collected.Results:Twenty-three PN patients showed clinical relief in skin lesions and itch,and a better quality of life.A consistent proportion of patients(95.7％)received at least a 16-week continuous treatment and achieved an IGA stage score 0/1(65.2％)and an IGA activity stage 0/1(95.7％).An increased number of patients achieved at least a 2-grade reduction in IGA stage score(82.6％).NRS values for itch,DLQI and POEM decreased from 8.48±1.44 to 1.13±0.81(P＜0.05),20.87±5.38 to 2.83±1.50(P＜0.05),and 21.30±4.13 to 2.61±1.37(P＜0.05),respectively,after 16-week dupilumab therapy.During the treatment,mild conjunctivitis occurred in two cases,relief was achieved after treatment with flumirone eye drops.And psoriasiform lesions in one case,after oral administration of compound glycyrrhizn and topical car-potriol ointment,the skin lesion basically subsided.Conclusion:Dupilumab is effective and safe in relieving itch and reduc-ing PN skin lesions.
NETL
NSTL
万方数据
